Related papers: Improved Prediction of Beta-Amyloid and Tau Burden…
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that severely impairs cognitive function and quality of life. Timely intervention in AD relies heavily on early and precise diagnosis, which remains challenging due to the…
The diagnosis of Alzheimer's disease (AD) in routine clinical practice is most commonly based on subjective clinical interpretations. Quantitative electroencephalography (QEEG) measures have been shown to reflect neurodegenerative processes…
Volume change measures derived from longitudinal MRI (e.g. hippocampal atrophy) are a well-studied biomarker of disease progression in Alzheimer's Disease (AD) and are used in clinical trials to track the therapeutic efficacy of…
Analysis and quantification of brain structural changes, using Magnetic resonance imaging (MRI), are increasingly used to define novel biomarkers of brain pathologies, such as Alzheimer's disease (AD). Network-based models of the brain have…
Alzheimer's disease (AD) is an irreversible neurodegenerative disorder that progressively destroys memory and other cognitive domains of the brain. While effective therapeutic management of AD is still in development, it seems reasonable to…
Alzheimer Disease poses a significant challenge, necessitating early detection for effective intervention. MRI is a key neuroimaging tool due to its ease of use and cost effectiveness. This study analyzes machine learning methods for MRI…
Alzheimer's Disease (AD) is a progressive neurodegenerative disease. Amnestic mild cognitive impairment (MCI) is a common first symptom before the conversion to clinical impairment where the individual becomes unable to perform activities…
Early diagnosis and discovery of therapeutic drug targets are crucial objectives for effective management of Alzheimer's Disease (AD). Current approaches for AD diagnosis and treatment planning are based on radiological imaging and largely…
Tau positron emission tomography (PET) is a critical diagnostic modality for Alzheimer's disease (AD) because it visualizes and quantifies neurofibrillary tangles, a hallmark of AD pathology. However, its widespread clinical adoption is…
Predicting whether someone with mild cognitive impairment (MCI) will progress to Alzheimer's disease (AD) is crucial in the early stages of neurodegeneration. This uncertainty limits enrollment in clinical trials and delays urgent…
Alzheimer's disease involves progressive tau accumulation and spread, leading to regional brain atrophy and disruption of large-scale functional networks. While tau propagation and tissue degeneration have been widely modeled, how atrophy…
Identifying amyloid-beta positive patients is crucial for determining eligibility for Alzheimer's disease (AD) clinical trials and new disease-modifying treatments, but currently requires PET or CSF sampling. Previous MRI-based deep…
Alzheimer's Disease (AD) is an irreversible neurodegenerative disease characterized by progressive cognitive decline as its main symptom. In the research field of deep learning-assisted diagnosis of AD, traditional convolutional neural…
Identifying and utilising various biomarkers for tracking Alzheimer's disease (AD) progression have received many recent attentions and enable helping clinicians make the prompt decisions. Traditional progression models focus on extracting…
Background:Cognitive assessments represent the most common clinical routine for the diagnosis of Alzheimer's Disease (AD). Given a large number of cognitive assessment tools and time-limited office visits, it is important to determine a…
Recent evidence has shown that structural magnetic resonance imaging (MRI) is an effective tool for Alzheimer's disease (AD) prediction and diagnosis. While traditional MRI-based diagnosis uses images acquired at a single time point, a…
Alzheimer's disease (AD) is characterized by progressive microstructural deterioration in brain tissue, yet conventional imaging and histopathology often lack the sensitivity needed to detect subtle early-stage changes. Here, we present a…
Deep learning has become an important tool for Alzheimer's disease (AD) classification from structural MRI. Many existing studies analyze individual 2D slices extracted from MRI volumes, while clinical neuroimaging practice typically relies…
Background: Alzheimers disease is a progressive neurodegenerative disorder and the main cause of dementia in aging. Hippocampus is prone to changes in the early stages of Alzheimers disease. Detection and observation of the hippocampus…
The pathology of Alzheimer's disease (AD) and mild cognitive impairment (MCI) is characterized by the presence of beta-amyloid extracellular plaques and neurofibrillary tangles containing hyper-phosphorylated tau. Individuals carrying the…